Pfizer [NYSE:PFE] raised its sales forecast for its Covid-19 vaccine this week by $2bn and told investors that the sale of other drugs has helped it to offset the impact of a strong dollar. But some analysts are not enthusiastic about the booster opportunity from its vaccines. The market liked the results, with shares up over 4% in the five days going into Tuesday's US trading session.
In this article we run the numbers through our AI engine and also get some independent feedback on the strength of its drugs offering as we go into the next quarter. Should investors in Pfizer stock be keeping faith or has most of the upside been undermined by the dollar now?
Want the full story? Access all of The Armchair Trader's content for just £5.99 per month.
Get weekly investment ideas and tips that will take your investing to the next level. Sign up here.
Free 28 day trial. Cancel anytime.
Log In or Sign Up to Armchair Trader+Already a member? Log in here:
Not a member? Sign up now or see the membership benefits
Further content of this article is not available as it is for members only. Please visit the registration page for Armchair Trader Plus+ for further details on the benefits of becoming a member.
